ID
45866
Descripción
Principal Investigator: Richard Wilson, McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA MeSH: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001005 This study of three metastatic melanoma patients utilized exome sequencing and RNA sequencing to help identify putative neoantigen peptides that could be further validated by standard immunological assays before design of a personalized vaccine. For each set of neoantigens identified and verified by standard assays, we designed GMP peptides that correspond to the top neoantigens, then used these to condition dendritic cell isolates from each patient. The conditioned dendritic cells were used as the vaccine in three rounds of vaccination, followed by monitoring for T cell memory response to each of the neoantigens.
Link
Palabras clave
Versiones (1)
- 14/10/23 14/10/23 - Simon Heim
Titular de derechos de autor
Richard Wilson, McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA
Subido en
14 de octubre de 2023
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs001005 Antigen Discovery in Melanoma
Subject ID, sample ID, and sample use variable obtained from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- StudyEvent: SEV1
- Subject ID, consent group, and affection status of participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Subject ID, sample ID, and sample use variable obtained from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Subject ID and gender of participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Sample ID, histological type, analyte type, body site where sample was obtained, tumor status of sample, and year when sample was collected from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
Similar models
Subject ID, sample ID, and sample use variable obtained from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- StudyEvent: SEV1
- Subject ID, consent group, and affection status of participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Subject ID, sample ID, and sample use variable obtained from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Subject ID and gender of participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Sample ID, histological type, analyte type, body site where sample was obtained, tumor status of sample, and year when sample was collected from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
C2348585 (UMLS CUI [1,2])